These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25393806)

  • 1. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Rochau U; Sroczynski G; Wolf D; Schmidt S; Jahn B; Kluibenschaedl M; Conrads-Frank A; Stenehjem D; Brixner D; Radich J; Gastl G; Siebert U
    Leuk Lymphoma; 2015; 56(8):2315-25. PubMed ID: 25393806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical decision analysis for first-line therapy of chronic myeloid leukemia.
    Rochau U; Sroczynski G; Wolf D; Schmidt S; Conrads-Frank A; Jahn B; Saverno K; Brixner D; Radich J; Gastl G; Siebert U
    Leuk Lymphoma; 2014 Aug; 55(8):1758-67. PubMed ID: 24160847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
    Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
    Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.
    Kulpeng W; Sompitak S; Jootar S; Chansung K; Teerawattananon Y
    Clin Ther; 2014 Apr; 36(4):534-43. PubMed ID: 24635968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.
    Li N; Zheng B; Cai HF; Yang J; Luo XF; Weng LZ; Zhan FM; Liu MB
    Clin Drug Investig; 2018 Jan; 38(1):79-86. PubMed ID: 29027641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
    Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation.
    Yamamoto C; Nakashima H; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Mashima K; Nagayama T; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Sugimoto M; Ishihara Y; Ashizawa M; Hatano K; Sato K; Oh I; Fujiwara SI; Ueda M; Ohmine K; Muroi K; Kanda Y
    Blood Adv; 2019 Nov; 3(21):3266-3277. PubMed ID: 31698458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
    Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B
    J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
    Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
    Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.
    Knopf KB; Divino V; McGarry L; Chen YJ; Pokras S; Munakata J; Taylor C; Ng D; Nieset C; Huang H
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e163-71. PubMed ID: 26411541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT; Cortes JE; Kantarjian HM
    Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis.
    Rochau U; Kluibenschaedl M; Stenehjem D; Kuan-Ling K; Radich J; Oderda G; Brixner D; Siebert U
    Leuk Res Treatment; 2015; 2015():982395. PubMed ID: 26783469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
    Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
    J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.
    Wu B; Liu M; Li T; Lin H; Zhong H
    Medicine (Baltimore); 2017 Jul; 96(29):e7445. PubMed ID: 28723754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
    Ghatnekar O; Hjalte F; Taylor M
    Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis.
    Sheng G; Chen S; Dong C; Zhang R; Miao M; Wu D; Tan SC; Liu C; Xiong T
    J Med Econ; 2017 Apr; 20(4):371-381. PubMed ID: 27936995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review.
    Fu J; Liu Y; Lin H; Wu B
    Clin Drug Investig; 2018 Dec; 38(12):1167-1178. PubMed ID: 30232698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis.
    Adel A; Abushanab D; Hamad A; Abdulla M; Izham M; Yassin M
    Cancer Control; 2021; 28():10732748211001796. PubMed ID: 33887995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.
    Ohm L; Lundqvist A; Dickman P; Höglund M; Persson U; Stenke L; Carlsson KS; Björkholm M
    Leuk Lymphoma; 2015 May; 56(5):1385-91. PubMed ID: 25139694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
    Kim K; McMillin GA; Bernard PS; Tantravahi S; Walker BS; Schmidt RL
    PLoS One; 2019; 14(12):e0226552. PubMed ID: 31869360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.